Eli Lilly’s Trulicity’s Broad CV Label Spotlights GLP-1 Rivalry
Direct Impact On Novo Nordisk’s Ozempic ‘Limited’
• By Sten Stovall
Trulicity is first type 2 diabetes drug approved to cut CV events in adults with and without heart disease. • Source: Shutterstock 
